Clinical trial · Observational
Find HDV and Determine Its Status in Turkey
Find HDV and Determine Its Status in Turkey "SITU(HD)VATION"
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of these study to determine the prevalence of hepatitis Delta virus (HDV) infections and the prognosis of HDV patients in Turkey's southeast. The investigators intend to arrange training sessions for 250 family physicians in Diyarbakir, Batman, Mardin, and Sanliurfa in order to determine those goals. The investigators will talk about diagnosing hepatitis B virus (HBV), HDV, hepatitis C virus (HCV), and Human Immunodeficiency virus (HIV) infections during these events. To ensure that patients with simultaneous HDV infection are evaluated for HIV/HCV and to detect liver fibrosis with a non-invasive method.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Hepatitis D Infection | — | UNRESOLVED | — |
| Cirrhosis, Liver | — | UNRESOLVED | — |
| Fibrosis, Liver | — | UNRESOLVED | — |
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Transmission Vertical | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Anti Delta | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Family Physicians
- description
- 1\. 250 Family Physicians
- label
- HDV Screening
- description
- 2\. 20,000 HBsAg positive patients
- interventionNames
- Diagnostic Test: Anti Delta
Primary outcomes (1)
- measure
- The frequency of HDV in certain regions of Southern Anatolia
- timeFrame
- 01.04.2024-30.09.2024
- description
- The primary endpoint of this study is to determine the frequency of HDV in certain regions of Southern Anatolia, and the virological and liver fibrosis status of patients with HDV infection.
Secondary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adults (Age≥18) * Being HBsAg positive for at least six months * Being a citizen of the Republic of Türkiye Exclusion Criteria: * There are no exclusion criteria in this study.
References
Publications (0)
Data not yet available